ELIFE:动物实验显示不同抗疟疾疫苗结合使用效果更佳

2018-06-28 张家伟 新华社

英国帝国理工学院研究人员领衔的团队通过动物实验发现,将两种不同的抗疟疾疫苗结合使用,比单独使用任何一种疫苗的抗疟疾效果都更好。

英国帝国理工学院研究人员领衔的团队通过动物实验发现,将两种不同的抗疟疾疫苗结合使用,比单独使用任何一种疫苗的抗疟疾效果都更好。

疟疾是一种由疟原虫引起的疾病,通过蚊子叮咬传播,其症状包括发热、头痛、呕吐等,不及时治疗可危及生命。

研究团队在实验中测试了两种类型的疟疾疫苗,TBV 和 PEV,两者都还处在不同阶段的临床试验过程中。在这项实验中,团队使用了小鼠以及一种经基因改良的寄生虫,它们与疟原虫在某些特征上具有相似性。

研究团队在美国 《电子生命》 期刊上报告说,动物实验表明这两种疫苗如单独使用,可将感染疟疾的风险分别降低 48% 和 68%,如将这两者结合使用能将感染风险降低 91%。

报告作者之一、帝国理工学院学者安德鲁·布拉格伯勒说,达到这一效果对公共健康来说会带来积极影响,尤其是对那些疟疾比较常见的地区。接下来,研究人员计划在更复杂的环境中验证不同疫苗结合使用的效果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677376, encodeId=7aec16e73768d, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Mar 27 08:45:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973050, encodeId=35a019e30504b, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 02 18:45:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068565, encodeId=cef6206856572, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Sep 16 07:45:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743792, encodeId=3e511e437929c, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Thu Nov 08 12:45:00 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677376, encodeId=7aec16e73768d, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Mar 27 08:45:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973050, encodeId=35a019e30504b, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 02 18:45:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068565, encodeId=cef6206856572, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Sep 16 07:45:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743792, encodeId=3e511e437929c, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Thu Nov 08 12:45:00 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2019-06-02 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677376, encodeId=7aec16e73768d, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Mar 27 08:45:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973050, encodeId=35a019e30504b, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 02 18:45:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068565, encodeId=cef6206856572, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Sep 16 07:45:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743792, encodeId=3e511e437929c, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Thu Nov 08 12:45:00 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-09-16 clmlylxy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677376, encodeId=7aec16e73768d, content=<a href='/topic/show?id=a31ae044675' target=_blank style='color:#2F92EE;'>#疟疾疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70446, encryptionId=a31ae044675, topicName=疟疾疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=327a27492917, createdName=dongjia2019, createdTime=Wed Mar 27 08:45:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973050, encodeId=35a019e30504b, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 02 18:45:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068565, encodeId=cef6206856572, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Sep 16 07:45:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743792, encodeId=3e511e437929c, content=<a href='/topic/show?id=7efd5545308' target=_blank style='color:#2F92EE;'>#抗疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55453, encryptionId=7efd5545308, topicName=抗疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e01d35226644, createdName=zhangying8800, createdTime=Thu Nov 08 12:45:00 CST 2018, time=2018-11-08, status=1, ipAttribution=)]

相关资讯

我国已建立覆盖疫苗全生命周期监管体系

我国现已建立起覆盖疫苗“研发—生产—流通—接种”全生命周期监管体系。上市疫苗全部实行国家批签发管理。

Emerging Mic Infect:广州生物院研制出新型腺病毒载体埃博拉疫苗

埃博拉病毒可引发严重的出血热疾病,致死率极高。2014 年非洲埃博拉疫情大爆发造成上万人死亡,今年 4 月以来刚果地区又爆发了埃博拉疫情,并有扩大传播的趋势,疫苗成为埃博拉疫情防控的最有效工具。中国科学院广州生物医药与健康研究院冯立强团队研制了一种利用 2 型腺病毒为载体的埃博拉病毒疫苗,6 月 6 日,相关研究成果以 An adenovirus serotype 2 vectored ebola

世卫组织将在刚果(金)试用埃博拉疫苗

世界卫生组织总干事谭德塞日前在刚果(金)首都金沙萨说,世卫组织计划在最新暴发埃博拉出血热疫情的刚果(金)西北部地区使用一种试验性埃博拉疫苗,这种疫苗将于本周运抵该国。

OncoImmunology:PDE5抑制剂和流感疫苗可限制肿瘤手术后扩散

究发现肿瘤切除手术后,治疗勃起功能障碍药物和流感疫苗可能有助于阻止癌症复发。

J Infection:婴儿期广泛接种乙肝疫苗大有裨益

2018年6月,发表在《J Infect》的一项由中国香港研究者进行的研究表明,30年的新生儿疫苗接种已经大幅降低了该项目覆盖的孕妇乙型肝炎病毒感染的产前患病率。

三十五年一无所获 艾滋病疫苗研发之路正确吗?

据国外媒体报道,20 世纪 80 年代末期,伯特? 多尔曼 (Burt Dorman) 准备退出疫苗接种领域。作为一名生物物理化学家,他花了数年时间成功经营一家制造动物疫苗的公司。这家公司开发出十几种针对猫科动物白血病和水疱性口炎等疾病的疫苗。随后多尔曼在一个新领域开创了一家致力于疾病诊断的新公司,致力于疾病诊断。